Analysts Anticipate Ascendis Pharma A/S (NASDAQ:ASND) Will Announce Earnings of -$2.06 Per Share


Share on StockTwits

Equities analysts expect Ascendis Pharma A/S (NASDAQ:ASND) to announce earnings of ($2.06) per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Ascendis Pharma A/S’s earnings. The highest EPS estimate is ($1.21) and the lowest is ($2.58). Ascendis Pharma A/S reported earnings of ($1.46) per share in the same quarter last year, which suggests a negative year over year growth rate of 41.1%. The company is expected to issue its next earnings report on Tuesday, May 18th.

On average, analysts expect that Ascendis Pharma A/S will report full year earnings of ($9.00) per share for the current fiscal year, with EPS estimates ranging from ($11.15) to ($7.14). For the next fiscal year, analysts anticipate that the company will report earnings of ($7.11) per share, with EPS estimates ranging from ($11.13) to ($3.58). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover Ascendis Pharma A/S.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Tuesday, March 9th. The biotechnology company reported ($2.64) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.84) by ($0.80). Ascendis Pharma A/S had a negative return on equity of 55.72% and a negative net margin of 4,042.79%. The firm had revenue of $0.64 million during the quarter, compared to analysts’ expectations of $2.71 million.

A number of equities research analysts recently commented on the company. Canaccord Genuity upped their target price on Ascendis Pharma A/S from $172.00 to $190.00 and gave the company a “buy” rating in a research report on Thursday, March 18th. Stifel Nicolaus began coverage on shares of Ascendis Pharma A/S in a report on Thursday, March 11th. They issued a “buy” rating on the stock. Credit Suisse Group reduced their target price on shares of Ascendis Pharma A/S from $178.00 to $176.00 and set an “outperform” rating for the company in a report on Wednesday, March 17th. Zacks Investment Research lowered shares of Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a report on Wednesday, April 21st. Finally, Oppenheimer lowered Ascendis Pharma A/S from an “outperform” rating to a “market perform” rating in a research note on Tuesday, March 30th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $192.22.

Several hedge funds have recently bought and sold shares of ASND. Simon Quick Advisors LLC acquired a new stake in shares of Ascendis Pharma A/S during the 4th quarter valued at about $33,000. Signaturefd LLC grew its holdings in Ascendis Pharma A/S by 26.1% in the first quarter. Signaturefd LLC now owns 357 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 74 shares during the period. ShoreHaven Wealth Partners LLC acquired a new stake in Ascendis Pharma A/S in the fourth quarter valued at approximately $92,000. US Bancorp DE increased its position in shares of Ascendis Pharma A/S by 23.1% in the first quarter. US Bancorp DE now owns 816 shares of the biotechnology company’s stock valued at $106,000 after buying an additional 153 shares in the last quarter. Finally, Private Ocean LLC acquired a new position in shares of Ascendis Pharma A/S during the 1st quarter worth approximately $124,000.

Shares of ASND stock traded down $6.90 during mid-day trading on Tuesday, reaching $138.39. The stock had a trading volume of 579,827 shares, compared to its average volume of 212,680. Ascendis Pharma A/S has a 1-year low of $119.11 and a 1-year high of $183.98. The firm has a market cap of $7.44 billion, a price-to-earnings ratio of -16.86 and a beta of 0.77. The business’s fifty day moving average is $132.86 and its 200-day moving average is $154.57.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, develops therapeutics for unmet medical needs. The company develops TransCon growth hormone, which completed Phase III clinical trials for growth hormone deficiency. It also develops TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for achondroplasia.

Read More: What does it mean to hold a stock in street name?

Get a free copy of the Zacks research report on Ascendis Pharma A/S (ASND)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.